Syngene International Ltd. (IN:SYNGENE)
:SYNGENE
Top Page
Syngene International Ltd.
(SYNGENE)
Select Model
Select Model
Rating:61Neutral
Price Target:
₹421.00
▼(-36.03% Downside)
Action:DowngradedDate:01/28/26
Solid financial performance (strong margins and low leverage) supports the score, but it is meaningfully offset by weak technicals (price below all major DMAs and bearish MACD) and an expensive valuation (high P/E with minimal dividend yield).
Positive Factors
High Profitability
Very high gross (74.12%) and EBITDA (31.46%) margins indicate durable pricing power and operational efficiency across discovery, development, and manufacturing services. These margins support reinvestment, fund strategic projects and cushion cyclical revenue swings, sustaining long-term cash generation.
Negative Factors
Modest Revenue Growth
Top-line growth is modest at ~4.4% annually, which may constrain the ability to scale fixed-capacity investments and to leverage operating leverage from high-margin services. Slower revenue expansion could limit long-term margin expansion and returns on recent capacity investments.
Read all positive and negative factors
Positive Factors
Negative Factors
High Profitability
Very high gross (74.12%) and EBITDA (31.46%) margins indicate durable pricing power and operational efficiency across discovery, development, and manufacturing services. These margins support reinvestment, fund strategic projects and cushion cyclical revenue swings, sustaining long-term cash generation.
Read all positive factors
Syngene International Ltd. (SYNGENE) vs. iShares MSCI India ETF (INDA)
Market Cap
₹160.83B
Dividend Yield0.19%
Average Volume (3M)59.93K
Price to Earnings (P/E)439.9
Beta (1Y)0.76
Revenue Growth8.57%
EPS Growth-2.93%
CountryIN
Employees6,510
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)1.80
Shares Outstanding402,939,420
10 Day Avg. Volume148,500
30 Day Avg. Volume59,929
Financial Highlights & Ratios
PEG Ratio-20.51
Price to Book (P/B)6.10
Price to Sales (P/S)7.91
P/FCF Ratio72.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)11.53
Revenue Forecast (FY)₹41.89B
Syngene International Ltd. Business Overview & Revenue Model
Company Description
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States, and internationally. The company provides discovery chemistry services, such as medicinal a...
How the Company Makes Money
Syngene makes money by providing outsourced R&D and manufacturing services to pharmaceutical and biotech customers under fee-for-service and longer-term contractual arrangements. Key revenue streams include: (1) Discovery and development services—...
Syngene International Ltd. Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
80
Positive
Cash Flow
78
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 37.47B | 36.42B | 34.89B | 31.93B | 26.04B | 21.84B |
| Gross Profit | 21.68B | 24.41B | 23.50B | 21.56B | 17.12B | 15.28B |
| EBITDA | 10.18B | 9.91B | 10.30B | 9.59B | 7.26B | 6.44B |
| Net Income | 4.68B | 4.96B | 5.10B | 4.64B | 3.96B | 4.05B |
Balance Sheet | ||||||
| Total Assets | 65.42B | 67.96B | 61.52B | 58.31B | 55.64B | 48.83B |
| Cash, Cash Equivalents and Short-Term Investments | 10.91B | 13.97B | 10.77B | 13.54B | 12.81B | 10.65B |
| Total Debt | 5.82B | 5.78B | 5.55B | 8.15B | 10.22B | 8.93B |
| Total Liabilities | 18.07B | 20.69B | 18.94B | 22.13B | 22.66B | 20.62B |
| Stockholders Equity | 47.35B | 47.27B | 42.58B | 36.18B | 32.98B | 28.21B |
Cash Flow | ||||||
| Free Cash Flow | -2.00B | 3.98B | 5.50B | 3.05B | 1.05B | 2.55B |
| Operating Cash Flow | -451.00M | 11.68B | 10.42B | 8.38B | 5.81B | 7.01B |
| Investing Cash Flow | 764.00M | -7.45B | -4.96B | -6.88B | -6.12B | -6.28B |
| Financing Cash Flow | -821.00M | -1.42B | -5.51B | -3.40B | -313.00M | 580.00M |
Syngene International Ltd. Technical Analysis
Negative
658.10
Price Trends
433.72
Negative
538.21
Negative
595.00
Negative
Market Momentum
-12.73
Negative
42.98
Neutral
35.87
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SYNGENE, the sentiment is Negative. The current price of 658.1 is above the 20-day moving average (MA) of 405.08, above the 50-day MA of 433.72, and above the 200-day MA of 595.00, indicating a bearish trend. The MACD of -12.73 indicates Negative momentum. The RSI at 42.98 is Neutral, neither overbought nor oversold. The STOCH value of 35.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:SYNGENE.
Syngene International Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | ₹584.58B | 59.42 | ― | 0.15% | 25.83% | 421.20% | |
63 Neutral | ₹566.77B | 91.56 | ― | 0.12% | 10.62% | -66.88% | |
62 Neutral | ₹345.30B | 151.95 | ― | 0.84% | -36.14% | -93.99% | |
61 Neutral | ₹160.83B | 439.86 | ― | 0.19% | 8.57% | -2.93% | |
61 Neutral | ₹284.90B | 27.13 | ― | 1.07% | -1.51% | 14.27% | |
53 Neutral | ₹613.60B | 35.61 | ― | 0.24% | 30.27% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:SYNGENE
Syngene International Ltd.
399.15
-301.04
-42.99%
IN:ASTERDM
Aster DM Healthcare Ltd.
666.45
166.48
33.30%
IN:BIOCON
Biocon Limited
350.00
33.87
10.71%
IN:GLAND
Gland Pharma Ltd.
1,729.20
347.47
25.15%
IN:GLENMARK
Glenmark Pharmaceuticals Limited
2,174.35
800.17
58.23%
IN:LAURUSLABS
Laurus Labs Ltd.
1,082.85
478.08
79.05%
Syngene International Ltd. Corporate Events
Syngene Updates Exchanges on Order Implementing NFAC Ruling in Tax Case
Mar 29, 2026
Syngene International Limited has notified stock exchanges that it has received an order dated February 6, 2026, giving effect to an earlier decision by the National Faceless Appeal Centre for assessment year 2016-17, which was communicated to the...
Syngene Closes Trading Window Ahead of FY26 Results
Mar 27, 2026
Syngene International has announced the closure of its trading window for dealings in the company’s securities from April 1, 2026, until 48 hours after the announcement of its audited financial results for the quarter and full year ending Ma...
Syngene secures relief as tax authority drops penalty in AY18 litigation
Mar 14, 2026
Syngene International Ltd. has disclosed that it received an order dated March 13, 2026 from the National Faceless Assessment Centre under Section 270A of the Income-tax Act relating to Assessment Year 2018-19. The communication follows earlier ta...
Syngene Publishes Q3 FY2026 Earnings Call Transcript on Website
Jan 29, 2026
Syngene International Ltd. has notified the stock exchanges that the transcript of its Q3 FY2026 earnings call, held on January 23, 2026, has been uploaded to the company’s website in compliance with SEBI’s disclosure regulations. The ...
Syngene Publishes December-Quarter Financial Results in Newspapers and Online
Jan 24, 2026
Syngene International Ltd. has notified stock exchanges that it has published its financial results for the quarter and nine months ended December 31, 2025, in the Financial Express (all-India edition) and Vijayavani (Bengaluru edition), in line w...
Syngene Extends and Expands Bristol Myers Squibb Research Alliance to 2035
Jan 19, 2026
Syngene International has extended and expanded its long-term strategic research collaboration with Bristol Myers Squibb through 2035, broadening the scope of integrated services from early discovery through development, manufacturing and clinical...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.